Recchia F, Passalacqua G, Rodorigo C, Belli L, Morgante A, Rabitti G
U.L.S.S. n. 2, Ospedale Civile di Avezzano, L'Aquila.
Minerva Med. 1989 Dec;80(12):1363-6.
A 52 years old female with hepatocellular carcinoma (HCC) was treated successfully with Tamoxifen. The tumor involved IV hepatic segment with hilar extension and biliary obstruction, was unresectable, and had been pretreated with hormone-chemotherapy. Tamoxifen treatment induced a PR of 6 months, with normalization of serum bilirubin, reduction of alfa-fetoprotein level and improvement of PS, and was free of toxicity. At disease progression intra-arterial chemotherapy with Cis platinum (CDDP) and 5-FU gave a further 4 months PR, until disease progression and exitus in hepatic coma. Tamoxifen therapy, even in the absence of E.R. assay is a useful tool in the management of HCC patients. Further randomized studies are necessary to ascertain the role of Tamoxifen in the treatment of HCC.
一名52岁的肝细胞癌(HCC)女性患者接受他莫昔芬治疗后获得成功。肿瘤累及肝IV段并伴有肝门部侵犯和胆道梗阻,无法切除,且此前已接受过激素化疗。他莫昔芬治疗诱导了6个月的部分缓解(PR),血清胆红素恢复正常,甲胎蛋白水平降低,体能状态(PS)改善,且无毒性。疾病进展时,顺铂(CDDP)和5-氟尿嘧啶(5-FU)动脉内化疗又带来了4个月的PR,直至疾病进展并死于肝昏迷。即使在未进行雌激素受体(E.R.)检测的情况下,他莫昔芬治疗仍是管理HCC患者的一种有用手段。有必要进行进一步的随机研究,以确定他莫昔芬在HCC治疗中的作用。